Lung cancer is the most common type of cancer and second leading cause of death in the US. There are significant variations in cancer-related mortality among geographical areas and at varying socioeconomic status level.
In the presence of effective adjunctive treatments after neoadjuvant chemoradiotherapy, local surgery is a feasible intervention that can substantially improve the quality of life of NSCLC patients. The benefit is not only confined to advanced stages of the disease.
Results from a recent clinical trial does not support an increased risk of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) associated with cigarette smoking, and there is no evidence of a high risk of non-small-cell lung cancer with a history of previous cancer.
Early signs of carcinoma, non-small-cell lung include decreased activity, loss of appetite, and weight loss. Early signs of carcinoma, non-small-cell lung can be noticeable in patients as young as 10 years of age.
For lung cancer, only surgical resection and radiotherapy are common and effective alternatives to active surveillance. Chemotherapy for lung cancer is also used frequently, and targeted therapy is available. For carcinoma, non-small-cell lung, surgical resection and radiotherapy are the common treatments. Fewer studies are available for other forms of lung cancer. The common treatments are also applicable for various types of carcinoma, non-small-cell lung.
Etrumadenant is a potent and selective antagonist of prostaglandin D2. It has the potential to have a therapeutic effect in several diseases, such as respiratory diseases, allergies, inflammatory disorders and pain. The development of etrumadenant is expected to continue for years to come. It now has a Phase 3 clinical trial in place and will go to market at least 7–10 years from now.
Common (>0.1%) side effects across all studied populations include: headache, nausea, dizziness, vomiting, dyspepsia, constipation, upper airway obstruction, cough, insomnia, and increased intracranial pressure. The incidence of upper airway obstruction is similar to that reported for previous anti-migraine drugs. These can be managed by reducing intake as needed. Severe hypersensitivity reactions were observed in one patient during an open‐label Study.\n\nEtumadac promotes mobilization of CD4+ T lymphocyte cells and of natural killer (NK) cells against tumor cells.
For carcinoma, non-small-cell lung, the overall 5-year death risk was 1.8%, and the relative risk of death in the treatment group was significantly lower than that of conventional therapy.
Etumeradenant is a new antimetastatic drug specifically designed by Pfizer for treatment of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). Clinical use of etrumadenant began in the United States in December 2016. Etumaric acid, or etrumadenant, is used in combination with other chemotherapy medicines that kill cancers by triggering the body's immune system's attack on cancer cells.
Etrumadenant significantly exceeded placebo in improving all primary and secondary response outcomes. Data from a recent study indicate that etrumadenant is a potentially effective antineoplastic. A Phase III trial with etrumadenant is currently underway.
There are several limitations in this small observational study of etrumadenant. Given the small number of patients treated within the present study, it must be ascertained that the results reflect the experience of patients with etrumadenant before making a definitive conclusion regarding its generalizability. Due to the observational nature of the study, the results cannot definitively establish causation as a contributor to the observed efficacy in patients in this retrospective study. The effect of etrumadenant on mortality was not assessed in this study.